SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Timber Pharmaceuticals, Inc. (TMBR) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 18/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TMBR
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio8.68
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-9.19
Book Value / Share$0.00
Revenue / Share$0.04
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.01 |
$0.00 |
$-52.3K |
- |
| 2014 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2015 |
$-13,030.90 |
$64K |
$-15.6M |
-24371.9% |
| 2016 |
$-7,710.93 |
$100K |
$-18.41M |
-18406% |
| 2017 |
$-1,567.94 |
$73K |
$-8.98M |
-12298.6% |
| 2018 |
$-1,340.11 |
$57K |
$-17.26M |
-30277.2% |
| 2019 |
$-29.31 |
$324.65K |
$-3.69M |
-1136.7% |
| 2020 |
$-48.15 |
$453.81K |
$-15.12M |
-3331.3% |
| 2021 |
$-13.15 |
$295.74K |
$-10.64M |
-3597.5% |
| 2022 |
$-9.19 |
$83.18K |
$-19.38M |
-23299% |
